Search Results - "Brohl, Andrew S"

The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation by Brohl, Andrew S., Kahen, Elliot, Yoder, Sean J., Teer, Jamie K., Reed, Damon R.

“…Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma. To more fully characterize the genomic landscape of this tumor type, we…”
Get full text

Monogenic and polygenic determinants of sarcoma risk: an international genetic study by Ballinger, Mandy L, PhD, Goode, David L, PhD, Ray-Coquard, Isabelle, Prof, James, Paul A, MBChB, Mitchell, Gillian, PhD, Niedermayr, Eveline, BSc, Puri, Ajay, Prof, Schiffman, Joshua D, Prof, Dite, Gillian S, PhD, Cipponi, Arcadi, PhD, Maki, Robert G, Prof, Brohl, Andrew S, MD, Myklebost, Ola, Prof, Stratford, Eva W, PhD, Lorenz, Susanne, PhD, Ahn, Sung-Min, MD, Ahn, Jin-Hee, MD, Kim, Jeong Eun, MD, Shanley, Sue, MD, Beshay, Victoria, PhD, Randall, Robert Lor, Prof, Judson, Ian, Prof, Seddon, Beatrice, PhD, Campbell, Ian G, Prof, Young, Mary-Anne, MSc, Sarin, Rajiv, Prof, Blay, Jean-Yves, Prof, O'Donoghue, Seán I, PhD, Thomas, David M, Prof

“…Summary Background Sarcomas are rare, phenotypically heterogeneous cancers that disproportionately affect the young. Outside rare syndromes, the nature,…”
Get full text

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy by Knepper, Todd C, Montesion, Meagan, Russell, Jeffery S, Sokol, Ethan S, Frampton, Garrett M, Miller, Vincent A, Albacker, Lee A, McLeod, Howard L, Eroglu, Zeynep, Khushalani, Nikhil I, Sondak, Vernon K, Messina, Jane L, Schell, Michael J, DeCaprio, James A, Tsai, Kenneth Y, Brohl, Andrew S

“…Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we…”
Get full text

Treatment pathway of bone sarcoma in children, adolescents, and young adults by Reed, Damon R., Hayashi, Masanori, Wagner, Lars, Binitie, Odion, Steppan, Diana A., Brohl, Andrew S., Shinohara, Eric T., Bridge, Julia A., Loeb, David M., Borinstein, Scott C., Isakoff, Michael S.

“…When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a…”
Get full text

Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma by Bridge, Julia A., Sumegi, Janos, Druta, Mihaela, Bui, Marilyn M., Henderson-Jackson, Evita, Linos, Konstantinos, Baker, Michael, Walko, Christine M., Millis, Sherri, Brohl, Andrew S.

“…Molecular diagnostics of sarcoma subtypes commonly involve the identification of characteristic oncogenic fusions. EWSR1-PATZ1 is a rare fusion partnering in…”
Get full text

Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis by Jinesh, Goodwin G., Brohl, Andrew S.

“…Metastasis is a pivotal event that accelerates the prognosis of cancer patients towards mortality. Therapies that aim to induce cell death in metastatic cells…”
Get full text

Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers by Jinesh, Goodwin G, Flores, Elsa R, Brohl, Andrew S

“…Triple negative breast cancers (TNBCs) are known to express low PGR, ESR1, and ERBB2, and high KRT5, KRT14, and KRT17. However, the reasons behind the…”
Get full text

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors by Shern, Jack F, Chen, Li, Chmielecki, Juliann, Wei, Jun S, Patidar, Rajesh, Rosenberg, Mara, Ambrogio, Lauren, Auclair, Daniel, Wang, Jianjun, Song, Young K, Tolman, Catherine, Hurd, Laura, Liao, Hongling, Zhang, Shile, Bogen, Dominik, Brohl, Andrew S, Sindiri, Sivasish, Catchpoole, Daniel, Badgett, Thomas, Getz, Gad, Mora, Jaume, Anderson, James R, Skapek, Stephen X, Barr, Frederic G, Meyerson, Matthew, Hawkins, Douglas S, Khan, Javed

“…Despite gains in survival, outcomes for patients with metastatic or recurrent rhabdomyosarcoma remain dismal. In a collaboration between the National Cancer…”
Get more information

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation by Brohl, Andrew S, Solomon, David A, Chang, Wendy, Wang, Jianjun, Song, Young, Sindiri, Sivasish, Patidar, Rajesh, Hurd, Laura, Chen, Li, Shern, Jack F, Liao, Hongling, Wen, Xinyu, Gerard, Julia, Kim, Jung-Sik, Lopez Guerrero, Jose Antonio, Machado, Isidro, Wai, Daniel H, Picci, Piero, Triche, Timothy, Horvai, Andrew E, Miettinen, Markku, Wei, Jun S, Catchpool, Daniel, Llombart-Bosch, Antonio, Waldman, Todd, Khan, Javed

“…The Ewing sarcoma family of tumors (EFT) is a group of highly malignant small round blue cell tumors occurring in children and young adults. We report here the…”
Get full text

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial by D'Angelo, Sandra P, Bhatia, Shailender, Brohl, Andrew S, Hamid, Omid, Mehnert, Janice M, Terheyden, Patrick, Shih, Kent C, Brownell, Isaac, Lebbé, Celeste, Lewis, Karl D, Linette, Gerald P, Milella, Michele, Georges, Sara, Shah, Parantu, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul T

“…BackgroundMerkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti–programmed…”
Get full text

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines by Welch, Darcy, Kahen, Elliot, Fridley, Brooke, Brohl, Andrew S, Cubitt, Christopher L, Reed, Damon R

“…Ewing Sarcoma (ES) is characterized by recurrent translocations between EWSR1 and members of the ETS family of transcription factors. The transcriptional…”
Get full text

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study by D'Angelo, Sandra P, Lebbé, Celeste, Mortier, Laurent, Brohl, Andrew S, Fazio, Nicola, Grob, Jean-Jacques, Prinzi, Natalie, Hanna, Glenn J, Hassel, Jessica C, Kiecker, Felix, Georges, Sara, Ellers-Lenz, Barbara, Shah, Parantu, Güzel, Gülseren, Nghiem, Paul

“…BackgroundAvelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a…”
Get full text

The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss by Setty, Bhuvana A, Jinesh, Goodwin G, Arnold, Michael, Pettersson, Fredrik, Cheng, Chia-Ho, Cen, Ling, Yoder, Sean J, Teer, Jamie K, Flores, Elsa R, Reed, Damon R, Brohl, Andrew S

“…Undifferentiated embryonal sarcoma of the liver (UESL) is a rare and aggressive malignancy. Though the molecular underpinnings of this cancer have been largely…”
Get full text

Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma by Jinesh, Goodwin G., Napoli, Marco, Smallin, Marian T., Davis, Andrew, Ackerman, Hayley D., Raulji, Payal, Montey, Nicole, Flores, Elsa R., Brohl, Andrew S.

“…A subset of hepatocellular carcinoma (HCC) overexpresses the chromosome 19 miRNA cluster (C19MC) and is associated with an undifferentiated phenotype marked by…”
Get full text

Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy by Welch, Darcy L., Fridley, Brooke L., Cen, Ling, Teer, Jamie K., Yoder, Sean J., Pettersson, Fredrik, Xu, Liping, Cheng, Chia-Ho, Zhang, Yonghong, Alexandrow, Mark G., Xiang, Shengyan, Robertson-Tessi, Mark, Brown, Joel S., Metts, Jonathan, Brohl, Andrew S., Reed, Damon R.

“…Osteosarcoma is the most common bone sarcoma in children and young adults. While universally delivered, chemotherapy only benefits roughly half of patients…”
Get full text

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma by Mullinax, John E, Hall, MacLean, Prabhakaran, Sangeetha, Weber, Jeffrey, Khushalani, Nikhil, Eroglu, Zeynep, Brohl, Andrew S, Markowitz, Joseph, Royster, Erica, Richards, Allison, Stark, Valerie, Zager, Jonathan S, Kelley, Linda, Cox, Cheryl, Sondak, Vernon K, Mulé, James J, Pilon-Thomas, Shari, Sarnaik, Amod A

“…Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma can be highly effective, but attrition due to progression before…”
Get full text

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma by Marin-Acevedo, Julian A, Withycombe, Bethany M, Kim, Youngchul, Brohl, Andrew S, Eroglu, Zeynep, Markowitz, Joseph, Tarhini, Ahmad A, Tsai, Kenneth Y, Khushalani, Nikhil I

“…Anti-PD1 therapy demonstrated impressive, prolonged responses in advanced cutaneous squamous cell carcinoma (CSCC). Therapy for ICI-refractory/ineligible…”
Get full text

Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma by Hicks, J Kevin, Henderson-Jackson, Evita, Duggan, Julia, Joyce, David M, Brohl, Andrew S

“…RAF family activating fusions have been described as a potentially targetable molecular finding in a subset of soft tissue sarcomas. To further expand upon the…”
Get full text

Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy by Hoogland, Aasha I., Brohl, Andrew S., Small, Brent J., Michael, Lauren, Wuthrick, Evan, Eroglu, Zeynep, Blakaj, Dukagjin, Verschraegen, Claire, Khushalani, Nikhil I., Jim, Heather S. L., Kim, Sungjune

“…Background Merkel cell carcinoma is a rare skin cancer associated with poor survival. Based on a previous Phase II trial of adults with advanced Merkel cell…”
Get full text

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma by Ramadoss, Tanya, Nichols, Matthew, Palacios, Christian, Eroglu, Zeynep, Markowitz, Joseph, Karapetyan, Lilit, Tarhini, Ahmad A, Wuthrick, Evan J, Sondak, Vernon K, Khushalani, Nikhil I, Tsai, Kenneth Y, Brohl, Andrew S

“…BackgroundAdvanced Merkel cell carcinoma (MCC) has a high response rate to immune checkpoint blockade (ICB) therapy, but the durability of responses once…”
Get full text